Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of TQB6411 for injection in adults with advanced lung cancer. This phase IbII clinical trial aims to find the recommended phase II dosage and assess how well the treatment works in shrinking tumors or controlling the disease. The study is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and focuses on patients aged 18 to 75 years with confirmed lung cancer. Participants will receive TQB6411 injections either every 21 days or every 28 days as treatment cycles. The study involves only one treatment group where all participants receive TQB6411. Each cycle of treatment is followed by assessments to monitor response and safety. The trial includes dose evaluation and efficacy measurement over several months, with extended follow-up for survival and side effects lasting up to three years. During the study, participants will undergo medical evaluations including laboratory tests, imaging scans to measure tumors, and monitoring of adverse events. Blood samples will be taken to study drug levels and antibodies. The main outcomes measured include tumor response rates, disease control, duration of response, progression-free and overall survival. Safety is closely monitored throughout the study. The total participation time may last up to three years, including treatment and follow-up visits.
Actively Recruiting
This trial investigates TQ05105 tablets in adults with intermediate or high-risk myelofibrosis, a type of bone marrow cancer. It includes two groups one studying how the drug behaves in the body in participants with different levels of kidney function, and another assessing the drugs safety and effect in those who have not responded well or cannot tolerate previous Janus kinase JAK inhibitor treatments. The study is a phase II, open-label, single-arm, multicenter trial. Participants receive TQ05105 tablets in 28-day treatment cycles. The first group focuses on pharmacokinetics to guide dosing for normal to moderate kidney impairment. The second group evaluates the drugs safety and potential benefits in participants with spleen enlargement and prior JAK inhibitor therapy that was ineffective or intolerable. Treatment continues with regular dosing and monitoring. During the study, participants undergo assessments including measurements of spleen volume reduction and various pharmacokinetic parameters such as drug concentration over time. Safety is monitored through recording adverse events during treatment and up to 4 weeks after the last dose. Additional outcomes include symptom assessments, survival rates, and blood transfusion needs. The study lasts up to several years, with primary measurements at 24 weeks and extended follow-up averaging three years.
Actively Recruiting
This research aims to evaluate whether the inhaled anesthetic desflurane provides heart protection and reduces the chance of serious major cardiac events after coronary artery bypass graft CABG surgery compared to the intravenous anesthetic propofol. Cardiac surgery carries high risks of severe complications that influence patient outcomes, and current evidence on the benefits of inhaled anesthetics in this setting is inconsistent. The study is a large, national, multi-center, randomized controlled trial enrolling elective CABG patients to determine the best anesthesia approach for reducing complications and mortality. Participants will be randomly assigned to one of two groups one receiving inhaled desflurane anesthesia maintained at 0.5-2 MAC with specific timing protocols during surgery, and the other receiving total intravenous anesthesia with propofol infusion at 3-8 mgkgh without inhaled anesthetics. Desflurane is given with careful dosing to maximize cardioprotective effects, including protocols for wash-in and wash-out if needed. Propofol is administered via targeted infusion or manual adjustment. Both groups undergo routine induction before anesthesia maintenance. During the study, participants will be closely monitored for major cardiac events and death within 30 days after surgery. Researchers will also track complications such as pulmonary, kidney, and neurological issues, length of ventilation and ICU stay, hospital readmissions, and mortality up to 90 days. Assessments include clinical evaluations and outcomes related to cardiac surgery recovery. The study lasts through hospitalization and includes follow-up for up to one year for some measures to understand long-term effects and safety.
Actively Recruiting
Metallo--lactamase-producing carbapenem-resistant Gram-negative bacteria MBL-CR-GNB are a serious global health threat due to their ability to break down almost all -lactam antibiotics. Current inhibitors like avibactam cannot stop metallo--lactamases, limiting treatment options. Researchers are studying the combination of ceftazidime-avibactam with aztreonam, which works together to fight these infections. This phase 4 clinical trial aims to compare different infusion methods for this combination in patients with complicated infections caused by MBL-CR-GNB. Participants will receive either a 3-hour simultaneous intravenous infusion of ceftazidime-avibactam 2.5g and aztreonam 2g every 8 hours, or a sequential infusion where ceftazidime-avibactam is given over 2 hours followed by aztreonam over 1 hour every 8 hours. The study is randomized and double-blinded, comparing the effects of these two dosing schedules. Both methods are being evaluated for their ability to reach effective drug levels and their impact on infection outcomes. During the trial, researchers will monitor patients for clinical cure rates within 14 days, microbiological eradication, and any adverse events. Assessments include genotypic testing to confirm bacterial resistance, clinical evaluations, and safety monitoring. The study will follow patients through their treatment period, with careful tracking of infection response and potential side effects to determine if one infusion method offers advantages over the other.
Actively Recruiting
Researchers are evaluating the efficacy and safety of oral minocycline in patients who have experienced an acute spontaneous intracerebral hemorrhage within 48 hours of onset. This prospective, multicenter, randomized, double-blind, placebo-controlled Phase III trial aims to improve patient outcomes and explore the effects of minocycline on venous neuroinflammation in this condition. Participants will be randomly assigned to receive either minocycline or a matching placebo for 5 days alongside standard medical care. The minocycline group will take an initial dose of 200 mg immediately after randomization, followed by 100 mg every 12 hours for a total of 10 doses. Those with swallowing difficulties may receive the medication through a nasal feeding tube. The trial includes screening, treatment, and follow-up phases with visits scheduled at screening, 72 hours, 7 days, 90 days, and 180 days after randomization. During the study, participants will undergo assessments including neurological evaluations and imaging at specified time points. Researchers will measure outcomes such as the modified Rankin Scale score at 90 days, changes in neurological scores, inflammation markers, and stroke recurrence. Safety and efficacy will be monitored through these evaluations, with total participation lasting up to 180 days post-randomization.
Actively Recruiting
Researchers are evaluating a chemotherapy-light treatment approach for newly diagnosed pediatric and adolescent patients with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia Ph B-ALL. This trial studies the use of the third-generation tyrosine kinase inhibitor TKI olverembatinib combined with the bi-specific T cell engager blinatumomab and the BCL-2 inhibitor venetoclax. The study aims to assess the effectiveness and safety of this modified treatment compared to prior standard protocols. The treatment plan includes olverembatinib used throughout the regimen, combined with vincristine and prednisone during the first two weeks, followed by blinatumomab for 28 days as induction therapy to improve response and reduce toxicity. Consolidation involves two cycles of high-dose methotrexate with blinatumomab and four doses of triple intrathecal therapy. The dosage of cytarabine is lowered in the second consolidation phase to reduce toxicity. Maintenance therapy adds dexamethasone and vincristine with alternating cycles of venetoclax or daunorubicin over five cycles. Cyclophosphamide and asparaginase are omitted to lessen side effects. Participants will undergo assessments including cerebrospinal fluid and blood tests to monitor olverembatinib levels and bone marrow evaluations with next-generation sequencing to track minimal residual disease. The primary outcome is measurable residual disease at day 48 after induction. Secondary outcomes include early disease response, event-free survival, overall survival, and relapse rates over several years. The study involves long-term follow-up for up to seven years to evaluate treatment outcomes and safety.
Actively Recruiting
Researchers are evaluating whether adding three new drugsdasatinib, venetoclax, and homoharringtonineto current treatment can improve outcomes for children newly diagnosed with T-cell acute lymphoblastic leukemia T-ALL. This study is conducted across multiple centers within the Chinese Childrens Cancer Group and focuses on increasing remission rates, enhancing event-free survival, and lowering relapse rates. The treatment plan varies by patient subgroup. All children receive dexamethasone during induction therapy. For patients with early T-cell precursor ETP or near-ETP T-ALL, venetoclax replaces daunorubicin in induction and interim therapies, with changes to chemotherapy regimens to reduce fertility impact. Non-ETP patients receive dasatinib after an initial phase, with some randomized to different doses of homoharringtonine during intensification and reinduction therapies. Maintenance therapy includes adjusted chemotherapy cycles to lessen long-term effects. Participants undergo regular assessments including bone marrow tests to measure minimal residual disease MRD and monitor response to treatment. Researchers track remission rates, event-free survival, relapse incidence, and treatment side effects over approximately 5 to 6.5 years. Drug sensitivity testing is also added to help guide treatment choices. Safety is closely monitored during and after treatment to assess adverse events and overall outcomes.
Actively Recruiting
Researchers are evaluating two conditioning regimens before allogeneic stem cell transplantation allo-HSCT in adults aged 16 to 55 with acute myeloid leukemia AML or myelodysplastic syndrome MDS. The goal is to compare outcomes using fludarabine combined with either busulfan alone or busulfan plus melphalan. This study aims to assess if adding melphalan lowers relapse rates after transplantation. Participants are randomly assigned to receive one of two drug regimens fludarabine with busulfan and melphalan, or fludarabine with busulfan alone. The doses include fludarabine 150 mgm2, busulfan either 6.4 mgkg with melphalan or 12.8 mgkg without melphalan, and melphalan 140 mgm2 for the combination group. This multi-center trial compares the transplant outcomes between these regimens. During the study, participants will be monitored for disease-free survival over two years as the main outcome. Additional measurements include overall survival, relapse rates, and non-relapse mortality at 100 days and two years post-transplant. The study involves regular follow-up visits and assessments to track treatment effects and safety until June 2026.
Actively Recruiting
Researchers are evaluating the effects of nucresiran compared to placebo in patients with transthyretin amyloidosis with cardiomyopathy, a condition involving abnormal protein buildup in the heart. This study aims to assess whether nucresiran can reduce deaths from any cause and cardiovascular events, and also improve patient-reported health status and quality of life. The trial is a Phase 3, randomized, double-blind study focused on treatment outcomes. Participants will be randomly assigned to receive either nucresiran 300 mg or a placebo, both given as subcutaneous injections every six months during the double-blind period lasting up to 32 months with a maximum of 5 years. After this period, all participants enter an open-label extension where everyone receives nucresiran 300 mg every six months. Patients may continue some background therapies as decided by their investigators. Throughout the study, participants will be monitored for mortality and cardiovascular events, including hospitalizations and urgent heart failure visits. Health status and quality of life will be assessed using questionnaires. Safety and efficacy are evaluated through regular assessments during the double-blind phase and ongoing follow-up during the extension. The total study duration extends up to approximately 7 years, including follow-up after the main treatment period.